Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

PharmaRoth Labs Inc (PK:ROTH)

Business Focus: Pharmaceuticals

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEC Form 4 filings for ROTH*US within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Jun 14, 2016 08:30 ET
PharmaRoth Labs Announces New Clinical Trials for Sucanon in Mexico
PharmaRoth Labs, Inc. (OTC PINK: ROTH), the exclusive producer, marketer, and distributor of SucanonĀ®, an oral Type-II Diabetes treatment, today announced that it has started new clinical trials in Mexico City, Mexico. The test is for recently diagnosed Type-II diabetic patients and will cover over 200 participants for a duration of 12 weeks. The trial will be conducted at the Centro Medico ABC in Mexico City.
Read full article
May 03, 2016 08:30 ET
PharmaRoth Labs Announces Integration of HSBC Credit Facilities
PharmaRoth Labs, Inc. (OTC PINK: ROTH), the exclusive producer, marketer, and distributor of SucanonĀ®, an oral Type-II Diabetes treatment, today announced that it has successfully closed on the integration of its "Automatic Invoice Discounting" credit facilities with HSBC Mexico S.A. ("HSBC"). The credit facilities allow the company to receive payment through HSBC, derived from both new and existing purchase orders.
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
N/A
--
--
Price to Sales - TTM
0.00
2.76
3.23
Price to Book - most recent quarter
--
2.07
2.17
Price to Cash Flow per share - TTM
--
12.19
13.95
Price to Free Cash Flow per share - TTM
--
16.08
25.10
See all valuations

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

PharmaRoth Labs, Inc. is a nutraceutical company that is focused on the prevention and treatment of healthcare diabetes. The Company is engaged in the production, marketing, and distribution of Sucanon, a clinically-tested herbal-based nutraceutical treatment for type II diabetes. Sucanon is a medication that helps the body make better use of its own insulin, the hormone that controls blood sugar levels.

See business summary

 

Twitter

Search (past week) for $ROTH

  • No tweets found